Viridian Therapeutics Inc
VRDN
查看详细走势图
29.250USD
+0.080+0.27%
收盘 02/06, 16:00（美东）报价延迟15分钟
2.41B总市值
亏损市盈率 TTM
盘中分时
1分
30分
1小时
日k
周k
月k
日k
今天
+0.27%
5天
-11.36%
1月
-3.56%
6月
+78.24%
今年开始到现在
-6.01%
1年
+64.70%
查看详细走势图
TradingKey Viridian Therapeutics Inc股票评分
单位: USD 更新时间: 2026-02-06操作建议
Viridian Therapeutics Inc当前公司基本面数据相对非常健康，最新ESG披露属于行业领先水平。增长潜力很大。当前估值合理，在生物技术与医疗研究行业排名15/392位。机构持股占比非常高，近一月多位分析师给出公司评级为买入。最高目标价40.41。中期看，股价处于平稳状态。近一个月，市场表现较差，但公司基本面和技术面得分较高。目前股价在压力位和支撑位之间，可以做区间波段操作。
Viridian Therapeutics Inc评分
压力支撑
由于公司未披露，未能获取相关数据
多维评测
本期评分
上期评分
公司舆情
过去24小时
热度
过冷
过热
中性
Viridian Therapeutics Inc亮点
亮点风险
Viridian Therapeutics, Inc. is a biopharmaceutical company focused on engineering and developing potential medicines for patients with serious and rare diseases. The Company is advancing multiple candidates in the clinic for the treatment of patients with thyroid eye disease (TED). The Company is conducting two global Phase 3 clinical trials (THRIVE and THRIVE-2) to evaluate the safety and efficacy of veligrotug in patients with active and chronic TED. It is also conducting two global Phase 3 clinical trials, REVEAL-1 and REVEAL-2, to evaluate the efficacy and safety of VRDN-003 in patients. Its advanced program, veligrotug, is a differentiated humanized monoclonal antibody targeting IGF-1R intravenously administered for the treatment of TED. In addition to its TED portfolio, the Company is advancing a novel portfolio of neonatal Fc receptor (FcRn) inhibitors, including VRDN-006 and VRDN-008, which has the potential to be developed in multiple autoimmune diseases.
业绩增长期
公司处于发展阶段，最新年度总收入302.00K美元
利润高增长
公司净利润处于行业前列，最新年度总收入302.00K美元
估值低估
公司最新PE估值-7.86，处于3年历史低位
机构减仓
最新机构持股99.38M股，环比减少7.79%
景顺投资公司持仓
明星投资者景顺投资公司持仓，最新持仓市值41.71K
分析师目标
根据
19
位分析师
买入
评级
40.412
目标均价
+38.16%
涨幅空间
数据免责声明：分析师评级与目标价由LSEG提供，仅供参考，不应当作投资建议
Viridian Therapeutics Inc新闻
即将为您带来更多新闻，敬请期待。。。
财务指标
每股收益
由于公司未披露，未能获取相关数据
营业总收入
由于公司未披露，未能获取相关数据
Viridian Therapeutics Inc简介
Viridian Therapeutics, Inc. is a biopharmaceutical company focused on engineering and developing potential medicines for patients with serious and rare diseases. The Company is advancing multiple candidates in the clinic for the treatment of patients with thyroid eye disease (TED). The Company is conducting two global Phase 3 clinical trials (THRIVE and THRIVE-2) to evaluate the safety and efficacy of veligrotug in patients with active and chronic TED. It is also conducting two global Phase 3 clinical trials, REVEAL-1 and REVEAL-2, to evaluate the efficacy and safety of VRDN-003 in patients. Its advanced program, veligrotug, is a differentiated humanized monoclonal antibody targeting IGF-1R intravenously administered for the treatment of TED. In addition to its TED portfolio, the Company is advancing a novel portfolio of neonatal Fc receptor (FcRn) inhibitors, including VRDN-006 and VRDN-008, which has the potential to be developed in multiple autoimmune diseases.
公司代码VRDN
公司Viridian Therapeutics Inc
CEOMahoney (Stephen)
网址https://www.viridiantherapeutics.com/
相关品种
